Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2024-2032
세계 폐동맥 고혈압 치료제 시장 규모는 2023년 77억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 4.6%의 연평균 성장률(CAGR)을 보이며 2032년까지 116억 달러에 달할 것으로 예측했습니다.
폐동맥 고혈압(PAH)은 심장과 폐를 연결하는 동맥의 고혈압을 특징으로 하는 생명을 위협하는 질환입니다. 폐동맥 고혈압은 심장과 폐를 연결하는 동맥의 고혈압을 특징으로 하는 생명을 위협하는 질환입니다. 동맥벽이 조여지고 좁아지면 혈액을 펌프질하는 심장에 더 많은 압력이 가해져 근육이 약해집니다. PAH는 호흡곤란, 피로감, 발목과 다리의 부종 등을 특징으로 하며, 심장이 혈액을 펌프질하는 기능이 저하되어 결국 심부전을 유발할 수 있습니다. 심초음파 검사, 컴퓨터 단층 촬영(CT) 검사, 흉부 엑스레이 검사, 환기-관류 검사 등 다양한 검사를 통해 진단할 수 있습니다. 일반적으로 엔도세린 수용체 길항제(ERA), 혈관 확장제, 칼슘 길항제(CCB), 항응고제, 이뇨제, 걱정당체 등 다양한 약물을 사용하여 치료합니다. 이러한 약물은 흡입, 주사, 경구 투여가 가능합니다.
심혈관 및 폐 질환의 유병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 또한, 이러한 질병에 취약한 노인 인구의 증가도 시장 성장을 촉진하고 있습니다. 이와 함께 과도한 알코올 섭취, 운동 부족, 건강에 해로운 식습관 등 생활습관의 변화로 인해 고혈압과 고지혈증의 위험이 증가하고 있습니다. 이와 더불어, PAH 치료를 위한 새로운 희귀 약물과 기술적으로 진보된 기기의 시장 개척이 시장 성장을 촉진하고 있습니다. 또한, PAH의 대체 치료법에 대한 대중의 인식이 높아지고 전 세계적으로 의료 인프라가 개선되면서 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문들
- 2023년 폐동맥 고혈압 치료제 세계 시장 규모는?
- 2024-2032년 폐동맥 고혈압 치료제 세계 시장 성장률 전망은?
- 폐동맥 고혈압 치료제 세계 시장을 이끄는 주요 요인은 무엇인가?
- COVID-19가 폐동맥 고혈압 치료제 세계 시장에 미치는 영향은?
- 약물 종류별 폐동맥 고혈압 치료제 세계 시장 현황은?
- 투여 경로별 폐동맥 고혈압 치료제 세계 시장 현황은?
- 폐동맥 고혈압 치료제 세계 시장의 주요 지역은?
- 폐동맥 고혈압 치료제 세계 시장 주요 진출 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 폐동맥 고혈압 치료제 세계 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 약제 클래스별
- 엔도텔린 수용체 길항제(ERAs)
- 혈관확장제
- 포스포디에스테라제-5(PDE-5) 억제제
- 가용성 구아닐레이트 사이클레이즈(sGC) 자극제
- 칼슘 길항제(CCBs)
- 프로스타사이클린과 프로스타사이클린 유사체
- 기타
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Actelion Pharmaceuticals Ltd(Johnson & Johnson)
- Arena Pharmaceuticals Inc.
- AstraZeneca PLC
- Bayer Aktiengesellschaft
- Daiichi Sankyo Company Limited
- Gilead Science Inc.
- GlaxoSmithKline PLC
- Merck KGaA
- Novartis International AG
- Pfizer Inc.
- United Therapeutics Corporation
ksm
The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.
Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.
The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and end user.
Breakup by Drug Class:
Endothelin Receptor Antagonists (ERAs)
Vasodilators
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Calcium Channel Blockers (CCBs)
Prostacyclin and Prostacyclin Analogs
Others
Breakup by Route of Administration:
Inhalation
Injectable
Oral Administration
Breakup by End User:
Hospitals
Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.
Key Questions Answered in This Report
- 1. What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2023?
- 2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2024-2032?
- 3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
- 4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
- 5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
- 6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
- 7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
- 8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 Endothelin Receptor Antagonists (ERAs)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Vasodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Calcium Channel Blockers (CCBs)
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Prostacyclin and Prostacyclin Analogs
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Inhalation
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Injectable
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Oral Administration
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Arena Pharmaceuticals Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 AstraZeneca PLC
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Bayer Aktiengesellschaft
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Daiichi Sankyo Company Limited
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Gilead Science Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 GlaxoSmithKline PLC
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Merck KGaA
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Novartis International AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Pfizer Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 United Therapeutics Corporation
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
